(Q51896176)

17 April 2018

title

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. (English)

1 reference

17 April 2018

0 references

1 reference

1 reference

4

1 reference

17 April 2018

author name string

Nathanael L Dirks

series ordinal

1

1 reference

17 April 2018

Arno Nolting

series ordinal

2

1 reference

17 April 2018

Andreas Kovar

series ordinal

3

1 reference

17 April 2018

publication date

24 January 2008

1 reference

17 April 2018

The Journal of Clinical Pharmacology

published in

1 reference

17 April 2018

volume

48

1 reference

17 April 2018

issue

3

1 reference

17 April 2018

page(s)

267-278

1 reference

17 April 2018

The EGFR as a target for anticancer therapy--focus on cetuximab

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Epidermal growth factor receptor (EGFR) signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

NONMEMory: a run management tool for NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

The effect of collinearity on parameter estimates in nonlinear mixed effect models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Population pharmacokinetic studies in pediatrics: issues in design and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Epidermal growth factor enhances TNF-alpha-induced priming of human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

Pharmacokinetics and Pharmacodynamics of Peptide and Protein Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007313393

21 January 2018

Identifiers

DOI

10.1177/0091270007313393

1 reference

17 April 2018

1 reference

17 April 2018